Eculizumab

Red

Brand Name(s):Soliris

Indication:Paroxysmal nocturnal haemoglobinuria and Atypical hemolytic uremic syndrome (Ahus) Myasthenia gravis (refractory generalized) Neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease

Rationale:1,2,8

Considered:Nov-11

Review Date:Sep-24

Comments:
The SPC has been updated with a new indication – neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease. ………………………… NHS England will commission emicizumab as prophylaxis in adults and children with severe congenital haemophilia A (defined as factor VIII level <1 IU/dL, or <1% of normal) without current inhibitors to prevent bleeding episodes.………..............................NICE HST1 Eculizumab for treating Atypical hemolytic uremic syndrome (aHUS). Information at:http://www.nice.org.uk/guidance/hst1/resources/eculizumab-for-treating-atypical-haemolytic-uraemic-syndrome-1394895848389 Jan 2015